title: [Upper aerodigestive tract cancers: clinical benefits of conformal radiotherapy and intensity modulation].
abstract: The conformal radiotherapy approach, three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT), is based on modern imaging modalities, efficient 3D treatment planning systems, sophisticated immobilization systems and rigorous quality assurance and treatment verification. The central objective of conformal radiotherapy is to ensure a high dose distribution tailored to the limits of the target volume while reducing exposure of normal tissues. These techniques would then allow further tumor dose escalation. Head-and-neck tumors are some of the most attractive localizations to test conformal radiotherapy. They combine ballistic difficulties due to particularly complex shapes (nasopharynx, ethmoid) and problems due to the number and low tolerance of neighbouring organs like parotids, eyes, brainstem and spinal cord. The therapeutic irradiation of head-and-neck tumors thus remains a challenge for the radiation oncologist. Conformal radiotherapy does have a significant potential for improving local control and reducing toxicity when compared to standard radiotherapy. However, in the absence of prospective randomized trials, it is somewhat difficult at present to evaluate the real benefits drawn from 3DCRT and IMRT. The published clinical reports on the use of conformal radiotherapy are essentially dealing with dosimetric comparisons on relatively small numbers of patients. Recently, a few publications have emphasized the clinical experience of several precursor teams with a suitable follow-up. This paper describes the current state-of-the-art of 3DCRT and IMRT in order to evaluate the impact of these techniques on head-and-neck cancers irradiation.
authors.affiliation: Département d'oncologie-radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France. philippe.giraud@curie.net
authors.forename: P
authors.initials: P
authors.lastname: Giraud
authors.forename: C
authors.initials: C
authors.lastname: Jaulerry
authors.forename: F
authors.initials: F
authors.lastname: Brunin
authors.forename: S
authors.initials: S
authors.lastname: Zefkili
authors.forename: S
authors.initials: S
authors.lastname: Helfre
authors.forename: I
authors.initials: I
authors.lastname: Chauvet
authors.forename: J C
authors.initials: JC
authors.lastname: Rosenwald
authors.forename: J M
authors.initials: JM
authors.lastname: Cosset
mesh_terms: D002490:Central Nervous System / Q000528:radiation effects; D002493:Central Nervous System Diseases / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D019583:Dose Fractionation, Radiation; D005123:Eye / Q000528:radiation effects; D005128:Eye Diseases / Q000209:etiology / Q000517:prevention & control; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D021621:Imaging, Three-Dimensional; D010306:Parotid Gland / Q000528:radiation effects; D011836:Radiation Tolerance; D011874:Radiometry; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D020266:Radiotherapy, Conformal / Q000009:adverse effects / Q000379:methods; D014987:Xerostomia / Q000209:etiology / Q000517:prevention & control